Web-based calculator accurately predicts cancer survival

Predicting a cancer patient's chance of survival allows individuals to make informed decisions, but many techniques are not especially accurate. In a study, published in BMJ, researchers tested a new web-based survival calculator in patients with bowel cancer.

Developed by researchers at the University of Nottingham and ClinRisk, a medical software company, the 'QCancer Colorectal Survival' calculator allows physicians and patients to make informed decisions on treatment options. Designed by Julia Hippisley-Cox and Carol Coupland, professors in the university's school of medicine, the calculator uses patient data from 1,500 general practices from the Egton Medical Information Systems (EMIS) computer system.

The tool was able to differentiate predictions for men and women from 44,000 patients, evaluating information based on risk factors like smoking history, body mass index, family history, previous illnesses and treatments. The study tested the calculator’s predictive abilities at one, five and 10 years for 15,214 bowel cancer patients from 305 different practices. Results showed the calculator provided strong models for the prediction of cancer survival outcomes as well as providing estimates for how mortality risk changes over time.

"Current methods of estimating survival tend to be unreliable and sometimes patients can be given a fairly misleading and unnecessarily gloomy prognosis based only on the grade and stage of their cancer, only to find that in reality they live much longer than these crude predictions when other information is taken into account,” said Hippisley-Cox. “The good news is that this new calculator which doctors and patients can access will offer a far more realistic estimate. We understand that not everyone will want to do this, of course, but some patients are very keen on this approach so it's an individual choice."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.